ABSTRACT
It was previously found that a negative EA-rosette test, showing EA-rosette-forming cells in a cervical cell suspension, excluded the presence of cells of invasive carcinoma (predictive value of 99.9%). This study on 2,462 patients confirmed the applicability of the EA-rosette test in screening for precancerous as well as cancerous lesions. In 98.6% of the cases of dysplasia, carcinoma in situ and invasive carcinoma, the cervical cell suspensions contained EA-rosette forming cells (the rosette test was positive). With a negative EA-rosette test, the probability of missing a specimen with class III cytology (mild/moderate dysplasia) was 1.4%, of missing one with class IV cytology (severe dysplasia/carcinoma in situ) was 0.8% and of missing one with class V cytology (invasive carcinoma) was 0.25%. The predictive value of a negative EA-rosette test was 98.6%. The false-negative rate for negative EA-rosette tests was 3.7% for invasive carcinoma, 17.5% for carcinoma in situ and severe dysplasia and 41.4% for mild to moderate dysplasia.
Subject(s)
Carcinoma in Situ/diagnosis , Rosette Formation , Uterine Cervical Neoplasms/diagnosis , Evaluation Studies as Topic , False Negative Reactions , Female , Humans , Uterine Cervical Dysplasia/diagnosis , Vaginal SmearsABSTRACT
The Fc-C'-receptor-positive cells were investigated in tumor cell suspensions from 196 malignant tumors. The number of EA (Fc) and EAC' (C') rosettes was determined; the rosette-forming cells were identified cytologically, the cell suspensions were exposed to carbon particles, and they were grown in tissue culture. The results suggest that Fc or C' receptors might be present in malignant tumor cells as well as in host defence (inflammatory) cells invading the tumor.
